GlassScriptPhysician profile
Lauren Gnagy
NPI 1609371632
$413.22
in general payments reported to CMS, 2019-2025
10 companies · $413 in 2025
The $413 reported for 2025 was more than what 92% of Hospice and Palliative Medicine (Family Medicine) providers received nationally (typical 2025 total: $78.57).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $413.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $110.10 | 2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $71.09 | 2025 | Trelegy Ellipta |
| Abbvie INC. | $50.45 | 2025 | |
| Lilly USA, LLC | $49.49 | 2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $35.06 | 2025 | The Cologuard Plus Collection Kit |
| Vertex Pharmaceuticals Incorporated | $23.42 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.43 | 2025 | Jardiance |
| Millicent US INC | $19.97 | 2025 | Femlyv |
| Noven Therapeutics, LLC | $19.87 | 2025 | Secuado, Xelstrym |
| Mayne Pharma Commercial LLC | $12.34 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Gnagy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.